Out-licensing

Surgical implant for treatment and prevention of post-operative infections

Collatamp G is a peri-operative implant utilizing Innocoll's CollaRx sponge technology to deliver the broad spectrum antibiotic, gentamicin, to a local tissue infection (or a site at risk of infection).

There are more than 40 clinical studies evaluating the performance of Collatamp G, either for treating localized infection or for preventing surgical site infections across a wide variety of surgical procedures. For example, a recently published clinical trial in 2000 patients undergoing open heart surgery by median sternotomy showed that application of Collatamp G reduced the frequency of post-operative sternal wound infections by more than 50% compared to systemic antibiotics alone. Similar or even greater reductions in the frequency of surgical site infections have been reported in colorectal and other abdominal procedures. Pharmaeconomic studies have demonstrated that Collatamp G leads to reduced treatment expenses and an overall cost saving for the hospital if used routinely.

The primary use of the product is for surgeries having a high risk of infection and/or where surgical site infection can lead to severe complications, including:

• Orthopedics (including treatment of bone infections)• Mixed tissue trauma • Cardiac surgery • Vascular surgery • Rectal extirpation • Pilonidal sinus • Abdominal surgery • Appendectomy

Collatamp G is approved in almost 50 countries across Europe, North America, Africa and the Middle East under the various trade names such as Collatamp® EG, Sulmycin® Implant, Garamycin® Schwamm, Duracoll®, Garacoll®, Garacol®, Gentacoll®, Gentacol® and Cronocol®. The product has an exemplary patient safety record based upon pharmacovigilance data collected over more than 15 years. In August 2007, Innocoll signed an agreement transferring worldwide registration and marketing rights, with exception of the US, to EUSA Pharma.

The product has both medicinal product and EU medical device status.

Phase III

Out-license and co-development in the US.